Bristol Myers Squibb Co. devoted half a page of its annual report to its diversity, equity and inclusion efforts, going so ...
Among adults with relapsed or refractory indolent B-cell non-Hodgkin lymphoma, the phase 2 TRANSCEND FL trial met its primary ...
Acadia Pharmaceuticals' forecasted revenues top $1bn in 2025. Find out why ACAD stock is a "Buy" with its profitable outlook ...
Jim Cramer, the host of Mad Money, recently pointed out a significant gap in the American education system, emphasizing that ...